Post-menopausal bleeding – Is transvaginal ultrasound a useful first-line investigation in tamoxifen users?

Ali Abdaal, Yusuf Mushtaq, L Khasati, Joseph Moneim, Farhaan Khan, H. Ahmed, Helen Bolton
In: Post Reproductive Health · 2018 · vol. 24(2) , pp. 72–78 · doi:10.1177/2053369118755190 · PMID:29402191 · W2790238497
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher

Abstract

Objective To evaluate the role of transvaginal ultrasound triage in women with a history of tamoxifen treatment who present with post-menopausal bleeding. Study design A retrospective review was undertaken of patients who presented with symptoms of post-menopausal bleeding and underwent ultrasound triage. Endometrial thickness and ultrasonographic features were then correlated with hysteroscopic and histopathological outcome data. The findings and outcomes for women with a history of tamoxifen use (tamoxifen group) were compared to those who had not taken tamoxifen (non-tamoxifen group). Results A total of 614 women with post-menopausal bleeding underwent transvaginal ultrasound triage, of whom 53 had a history of current or previous tamoxifen treatment. An endometrial thickness of ≥5 mm or the presence of other abnormal features was used to triage women to further investigation by hysteroscopy and biopsy. Endometrial thickness was significantly greater in the tamoxifen group (11 mm vs. 6 mm). Nearly all of the tamoxifen group were triaged to further investigation (98.1%), compared with significantly fewer in the non-tamoxifen group (68.3%) Overall, the incidence of endometrial pathology was also significantly higher in tamoxifen patients (43.4% vs. 31.7%). Conclusion For women presenting with post-menopausal bleeding, the use of transvaginal ultrasound as a triage tool is rarely helpful in evaluating women who have a history as tamoxifen use, as most will require further investigation with hysteroscopy and biopsy. A post-menopausal bleeding protocol that omits transvaginal ultrasound for women with a history of tamoxifen use may be an appropriate and effective pathway for managing these patients.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

References (35)

SciLite annotations

chemicals 10
tamoxifen tamoxifen tamoxifen tamoxifen tamoxifen tamoxifen tamoxifen tamoxifen tamoxifen tamoxifen

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
scilite
last seen: 2026-05-18T04:26:01.642840+00:00
License: CC0 · commercial use OK